bioRxiv · 10.1101/2025.11.07.686998
Retargeted adenoviruses for local IgA and CD47 blocker production as a novel cancer therapy
Abstract
Despite advances in IgG-based cancer immunotherapy, challenges remain in effectively engaging innate immune responses against solid tumors. Here, IgA antibodies hold promise due to their ability to activate neutrophils and macrophages. We present a novel retargeted adenovirus-mediated approach that transforms cancer cells into "biofactories" for localized production of monomeric or dimeric IgA antibodies and a CD47 blocker to potentiate the effect of IgA antibodies. With our approach tumor cells effectively produced IgA antibodies against tumor antigens such as EGFR or EpCAM and a soluble SIRP-Fc fusion protein, which blocks the CD47-SIRP axis. In a perfused tumor-on-a-chip model, locally produced IgA triggered neutrophil- and macrophage-mediated tumor cell killing, further potentiated by SIRP-Fc co-production. In FcRI-transgenic, tumor-bearing mice, intratumoral adenoviral injection induced strong local IgA and SIRP-Fc expression, immune cell infiltration, and more than 50% tumor volume reduction after a single treatment. We found that dimeric IgA exerts stronger effects than monomeric IgA, which is of particular interest since dimeric IgA necessitates a local production approach. Together, these results demonstrate that adenovirus-mediated, tumor-restricted delivery of IgA antibodies and CD47 blockade effectively engages innate immune mechanisms, providing a promising new avenue to enhance cancer immunotherapy. Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=93 SRC="FIGDIR/small/686998v1_ufig1.gif" ALT="Figure 1"> View larger version (30K): org.highwire.dtl.DTLVardef@183dd88org.highwire.dtl.DTLVardef@452624org.highwire.dtl.DTLVardef@1cb10e8org.highwire.dtl.DTLVardef@c2fa85_HPS_FORMAT_FIGEXP M_FIG C_FIG
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Chernyavska, M., Hartmann, K. P., Jansen, M., Baumann, N., Kolibius, J., Bruecher, D., Kristoforus, T., Peters, R. H. W., Huijs, L., Laarveld, D., Weiss, F., Burger, R., Lustig, M., Gimenez de Assis, N., Schmid, M., Leusen, J. H. W., Valerius, T., Plueckthun, A., Verdurmen, W. P. R.. 2025-11-07. Retargeted adenoviruses for local IgA and CD47 blocker production as a novel cancer therapy. https://doi.org/10.1101/2025.11.07.686998
Cite the original work for its findings. Save a collection to share your selection of sources.